1. Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial
- Author
-
Thomas, R, Burger, R, Harper, A, Kanema, S, Mwenge, L, Vanqa, N, Bell-Mandla, N, Smith, P, Floyd, S, Bock, P, Ayles, H, Beyers, N, Donnell, D, Fidler, S, Hayes, R, Hauck, K, Hargreaves, J, Watson-Jones, D, Godfrey-Faussett, P, Cori, A, Pickles, M, Mandla, N, Yang, B, James, A, Vermaak, R, Makola, N, Hoddinott, G, Naidoo, V, Bond, V, Simwinga, M, Mwinga, A, Kosloff, B, Limbada, M, Bwalya, J, Ngulube, C, Fraser, C, Eshleman, S, Agyei, Y, Cummings, V, Catalano, D, Emel, L, Bunts, L, Noble, H, Burns, D, Kouda, A, Sista, N, Moore, A, White, R, Headen, T, Miller, E, Hinson, K, Vermund, S, Barnes, M, Horn, L, Mwango, A, Baldwin, M, Wolf, S, and Hughes, E
- Subjects
lcsh:Public aspects of medicine ,virus diseases ,lcsh:RA1-1270 - Abstract
Background The life expectancy of HIV-positive individuals receiving antiretroviral therapy (ART) is approaching that of HIV-negative people. However, little is known about how these populations compare in terms of health-related quality of life (HRQoL). We aimed to compare HRQoL between HIV-positive and HIV-negative people in Zambia and South Africa. Methods As part of the HPTN 071 (PopART) study, data from adults aged 18–44 years were gathered between Nov 28, 2013, and March 31, 2015, in large cross-sectional surveys of random samples of the general population in 21 communities in Zambia and South Africa. HRQoL data were collected with a standardised generic measure of health across five domains. We used β-distributed multivariable models to analyse differences in HRQoL scores between HIV-negative and HIV-positive individuals who were unaware of their status; aware, but not in HIV care; in HIV care, but who had not initiated ART; on ART for less than 5 years; and on ART for 5 years or more. We included controls for sociodemographic variables, herpes simplex virus type-2 status, and recreational drug use. Findings We obtained data for 19 750 respondents in Zambia and 18 941 respondents in South Africa. Laboratory-confirmed HIV status was available for 19 330 respondents in Zambia and 18 004 respondents in South Africa; 4128 (21%) of these 19 330 respondents in Zambia and 4012 (22%) of 18 004 respondents in South Africa had laboratory-confirmed HIV. We obtained complete HRQoL information for 19 637 respondents in Zambia and 18 429 respondents in South Africa. HRQoL scores did not differ significantly between individuals who had initiated ART more than 5 years previously and HIV-negative individuals, neither in Zambia (change in mean score −0·002, 95% CI −0·01 to 0·001; p=0·219) nor in South Africa (0·000, −0·002 to 0·003; p=0·939). However, scores did differ between HIV-positive individuals who had initiated ART less than 5 years previously and HIV-negative individuals in Zambia (−0·006, 95% CI −0·008 to −0·003; p Interpretation ART is successful in helping to reduce inequalities in HRQoL between HIV-positive and HIV-negative individuals in this general population sample. These findings highlight the importance of improving awareness of HIV status and expanding ART to prevent losses in HRQoL that occur with untreated HIV progression. The gains in HRQoL after individuals initiate ART could be substantial when scaled up to the population level. Funding National Institute of Allergy and Infectious Diseases, National Institute on Drug Abuse, National Institute of Mental Health, President's Emergency Plan for AIDS Relief, International Initiative for Impact Evaluation, the Bill & Melinda Gates Foundation.
- Published
- 2017